⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 1 hour ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 1 hour ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT May 20, 2026

Topiramat 1A Pharma 100 mg - Filmtabletten 100 mg (Filmtablette)

📷 Wikipedia: Topiramate · Source
Topiramat 1A Pharma 100 mg - Filmtabletten 100 mg (Filmtablette)
📷 Wikipedia: Topiramate · Source
Topiramat 1A Pharma 100 mg film-coated tablets are unavailable due to manufacturing shortages.
⚠️
Shortage ongoing
TOPIRAMAT is currently in short supply in AT.
📈 Timeline
7 days active so far
May 21, 2026 May 27, 2026

What is this? Topiramat is a medicine used to treat epilepsy and prevent migraines. It comes as 100 mg tablets.

What's happening? The maker cannot produce enough of these tablets right now. They ran out on 20 May 2026.

Does this affect me? If you take Topiramat 100 mg tablets, you may not be able to get them until supply returns.

What should I do? Ask your pharmacist or doctor for advice on other options while this shortage lasts.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
TOPIRAMAT
Agency-published detail

ATC: N03AX11 · Reason: Kapazitätsengpässe bei der Herstellung · Marketing authorisation holder: 1 A Pharma GmbH, Jakov-Lind-Straße 5/3.05, 1020 Wien, Österreich · Affected packs: 60 Stück Schachtel, Blisterpackung [Nicht verfügbar, since 2026-05-20]

First published
May 20, 2026
Last refreshed by us
13 hours ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

High AT 1 month ago

Topiramat-ratiopharm 25 mg Filmtabletten 25 mg (Filmtablette)

Topiramat-ratiopharm 25 mg film-coated tablets (25 mg per tablet) are subject to a parallel export ban. Supply is delayed.
High AT 1 month ago

Topiramat 1A Pharma 200 mg - Filmtabletten 200 mg (Filmtablette)

Topiramate 1A Pharma 200 mg film-coated tablets are currently unavailable due to manufacturing capacity shortages. Parallel export is prohibited.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Topiramat 1A Pharma 100 mg - Filmtabletten 100 mg (Filmtablette). Topiramat 1A Pharma 100 mg film-coated tablets are unavailable due to manufacturing shortages.
▸ When was this alert issued?
This alert was issued on May 20, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.